Twinrix Adult

RSS

hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 24/05/2023

Authorisation details

Product details
Name
Twinrix Adult
Agency product number
EMEA/H/C/000112
Active substance
  • hepatitis A virus (inactivated)
  • hepatitis B surface antigen
International non-proprietary name (INN) or common name
hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)
Therapeutic area (MeSH)
  • Hepatitis B
  • Hepatitis A
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07BC20
Publication details
Marketing-authorisation holder
GlaxoSmithKline Biologicals S.A.
Revision
23
Date of issue of marketing authorisation valid throughout the European Union
19/09/1996
Contact address
Rue de l'Institut, 89
B-1330 Rixensart
Belgium

Product information

26/04/2023 Twinrix Adult - EMEA/H/C/000112 - WS2365

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
1 rating
1 rating